Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Researchers determine the novel medical target of angiogenesis for ccRCC patients

Researchers determine the novel medical target of angiogenesis for ccRCC patients

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening